行情

APLT

APLT

Applied
NASDAQ

实时行情|Nasdaq Last Sale

40.85
-1.93
-4.51%
交易中 10:49 02/24 EST
开盘
41.87
昨收
42.78
最高
42.24
最低
40.67
成交量
4.40万
成交额
--
52周最高
57.39
52周最低
7.95
市值
6.97亿
市盈率(TTM)
-79.7852
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测APLT价格均价为50.67,最高价位65.00,最低价为43.00。

EPS

APLT 新闻

更多
  • The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
  • Zacks · 3天前
  • US Dollar Flexes Muscles Against Other Currencies: 5 Winners
  • Zacks · 4天前
  • 3 Top Biotech Stocks to Buy in February
  • MotleyFool.com · 02/09 13:29
  • The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
  • Benzinga · 02/05 12:43

所属板块

生物技术和医学研究
-2.32%
制药与医学研究
-2.16%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

APLT 简况

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.
展开

微牛提供Applied Therapeutics Inc(NASDAQ-APLT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的APLT股票新闻,以帮助您做出投资决策。